보고서 요약(국문)

개요
전 세계 망막 신생혈관 시장은 2022년 YY백만 달러에 도달했으며, 2023년부터 2030년까지 연평균 성장률(CAGR) YY%로 성장하여 2030년에는 YY백만 달러에 이를 것으로 예상됩니다.
망막 신생혈관증은 눈 뒤쪽의 빛에 민감한 조직인 망막에 새로운 혈관이 비정상적으로 생성되는 병리학적 질환입니다. 치료하지 않고 방치할 경우, 여러 안과 질환과 관련된 이 질환은 심각한 시력 문제 또는 실명을 유발할 수 있습니다.
이러한 비정상적인 혈관의 생성은 흉터, 황반 부종, 망막 출혈 등 여러 문제를 일으켜 시력을 심각하게 손상시킬 수 있습니다. 추가적인 시력 손실을 막기 위해서는 망막 신생혈관증을 정확하게 진단하고 치료해야 합니다.
망막 신생혈관 시장은 특히 신흥 경제국에서 당뇨병 유병률이 증가함에 따라 상당한 영향을 받고 있습니다. 망막 신생혈관 형성에 크게 기여하는 질환 중 하나는 당뇨병성 망막증이며, 당뇨병 환자 수 증가와 함께 치료가 필요한 환자 수도 늘어나고 있습니다.
습성 황반변성(AMD)을 포함한 연령 관련 안질환은 고령 인구에서 더욱 흔해지고 있습니다. 세계 인구 고령화에 따라 이러한 질환으로 인한 망막 신생혈관 형성을 조절하기 위한 치료법에 대한 수요가 증가하고 있습니다.
시장 동향: 주요 동인
당뇨병성 망막증에 대한 관심 증가
당뇨병의 가장 흔한 미세혈관병증 합병증인 당뇨병성 망막증(DR)은 전 세계적으로 1억 명 이상에게 영향을 미치며, 선진국에서 시력 손상 및 법적 실명의 주요 원인입니다. DR은 전통적으로 증식성 당뇨병성 망막증(PDR)과 비증식성 당뇨병성 망막증(NPDR)으로 구분됩니다. 비증식성 당뇨병성 망막병증(NPDR)에서 증식성 당뇨병성 망막병증(PDR)으로의 진행은 신생혈관 형성의 시작으로 특징지어지며, 이는 망막 내 출혈, 경성 및 연성 삼출물, 면화반점, 미세동맥류, 정맥 직경 이상, 망막 내 미세혈관 이상, 그리고 황반 및 주변 모세혈관의 비관류를 특징으로 합니다.
VEGF는 치밀연접 단백질의 인산화를 촉진하여 망막 모세혈관의 투과성을 증가시킵니다. 또한, 증가된 세포횡단수송, 활성화된 NOS 매개 과정, 오클루딘, 카테닌, 카드헤린을 포함한 다양한 세포간 분자의 변화 유도, 그리고 세포횡단수송 증가 모두 VEGF 관련 과투과성에 기여합니다. 주로 VEGF-A 동형에 의해 조절되는 이러한 모든 VEGF 관련 현상은 매우 복잡한 일련의 추가적인 활동 및 매개체와 함께 당뇨병성 망막병증의 흔한 합병증인 당뇨병성 황반부종(DME)의 발생 및 진행을 유발합니다.

망막 질환의 안구 내 치료에 대해 FDA 승인을 받은 최초의 약물은 페가프타닙(Macugen, Eyetech/Pfizer)입니다. 이 물질은 VEGF165 동형의 헤파린 결합 도메인에 우선적으로 결합하는 페길화된 압타머입니다.
환자의 인식 부족
망막 신생혈관의 징후와 위험성에 대한 환자와 의료진의 인식 부족으로 진단 및 치료 시작이 지연될 수 있습니다. 특히 자원이 부족한 지역에서는 전문 안과 시설과 자격을 갖춘 안과의사의 부족으로 치료가 지연되거나 기대에 미치지 못할 수 있습니다. 항 VEGF 주사와 같은 망막 신생혈관 치료는 감염, 망막 박리, 안압 상승과 같은 위험 및 부작용을 수반할 수 있습니다. 일부 환자는 이러한 위험 때문에 치료를 받지 않기로 선택할 수 있습니다.
세분화 분석
전 세계 망막 신생혈관 시장은 제품 유형, 최종 사용자 및 지역별로 세분화됩니다. 항VEGF 치료제 부문은 시장 점유율의 약 48.4%를 차지했습니다.
아플리버셉트(Eylea; Regeneron), 라니비주맙(Lucentis; Genentech, 캘리포니아), 베바시주맙(Avastin; Genentech)은 황반변성(AMD) 치료에 가장 많이 사용되는 VEGF-A 경로 치료제입니다. 항VEGF 약물은 습성 황반변성 치료 방식에 변화를 가져왔습니다.
베바시주맙은 Hoffmann-La Roche사의 Avastin이라는 상품명으로 판매되는 148kDa 크기의 완전 인간화 IgG1 항체로, VEGF-A 동형 단백질에 결합합니다. 이 항체는 원래 암 치료를 위해 개발되었으며, 망막 질환에 대한 유리체강 내 투여는 여전히 "오프라벨" 치료로 간주됩니다. 베바시주맙은 순수 항VEGF 항체로서, 신생혈관 생성 및 VEGF 유도 혈관 투과성 증가를 억제하는 것이 주요 효과입니다. 작용 기전은 비교적 간단합니다.

항혈관내피성장인자(anti-VEGF) 약물은 습성 황반변성(wet AMD) 치료의 표준 치료법으로 여겨지지만, 실제로는 치료 비용 때문에 최상의 임상 결과를 얻기 어려운 경우가 많습니다. 현재 사용되는 항혈관내피성장인자 약물의 비용은 오리지널 생물학적 제제와 효능 및 안전성이 동등한 생물학적 제제인 바이오시밀러 개발을 통해 절감될 수 있습니다.
항혈관내피성장인자 치료는 다양한 망막 질환에 유용하고 효과적이지만, 높은 비용과 침습적인 시술 특성으로 인해 환자와 의료 시스템에 상당한 부담을 주고 있습니다.
지리적 분석
선진 의료 인프라
북미는 전 세계 망막 신생혈관 시장에서 지배적인 위치를 차지하고 있습니다. 미국에서는 매년 1,100~1,500명의 신생아가 의학적 치료가 필요할 정도로 심각한 미숙아 망막병증(ROP)을 겪습니다. 임신 31주 이전에 태어났거나 출생 시 체중이 1,500g(3.3파운드) 미만인 영아가 이 희귀 안질환에 자주 걸립니다. 이러한 신생아들은 망막 혈관 이상(망막 신생혈관 형성)이 발생할 위험이 있으며, 이는 망막 박리와 비가역적인 시력 손실로 이어질 수 있습니다. 망막 혈관은 일반적으로 만삭(임신 9개월) 이후에야 완전히 발달합니다. 미숙아 망막병증(ROP)은 경미한 경우 자연적으로 호전될 수 있지만, 심각한 경우에는 실명 및 시력 손상을 예방하기 위해 치료가 필요할 수 있습니다.
2022년 6월, 바이오젠(Biogen Inc.)과 삼성바이오에피스(Samsung Bioepis Co., Ltd.)는 루센티스(LUCENTIS, 라니비주맙)의 바이오시밀러인 바이오비즈(BYOOVIZ, 라니비주맙-누나)를 미국에서 출시했습니다. 바이오비즈는 2022년 7월부터 미국 전역의 주요 유통업체를 통해 시판되고 있으며, 의료진 참여, 홍보 활동, 전문 협회 및 환자 옹호 단체와의 협력이 이미 시작되었습니다. 2021년 9월, FDA는 근시성 맥락막 신생혈관, 망막 정맥 폐쇄 후 황반 부종, 그리고 신생혈관성(습성) 연령 관련 황반변성(AMD) 치료제로 BYOOVIZ를 승인했습니다.
2023년 4월, 임상 단계 회사인 Adverum Biotechnologies, Inc.는 2상 LUNA 임상시험에서 평가 중인 이소베로겐 소로파르보벡(Ixo-vec, 이전 명칭 ADVM-022)의 두 가지 용량과 습성 AMD 치료에서 양측 눈 단계적 투여 가능성을 뒷받침하는 비임상 데이터를 발표했습니다.
COVID-19 영향 분석
2019년 말 발생한 COVID-19 팬데믹은 전 세계 산업, 특히 전 세계 망막 신생혈관 시장에 전례 없는 어려움을 초래했습니다. 봉쇄 조치, 제한, 그리고 전염병 유행 기간 동안 의료기관 방문에 대한 환자들의 불안감으로 인해 망막 신생혈관 및 관련 안과 질환의 진단 및 치료가 지연되었습니다. 팬데믹으로 인해 신약 개발 임상 연구가 연기되거나 일시적으로 중단되었을 수 있으며, 이는 신약 개발 및 시장 출시 가능성에 영향을 미쳤을 수 있습니다.
경쟁 환경
주요 글로벌 시장 참여 기업으로는 Regeneron Pharmaceuticals Inc., Biogen, Notal Vision, Inc., Novartis AG, Adverum Biotechnologies, Inc., Genentech, Inc., Bayer AG 등이 있습니다.
주요 개발 사항
• 2023년 2월, Regeneron Pharmaceuticals, Inc.는 미국 식품의약국(FDA)이 미숙아 망막병증 치료를 위한 EYLEA(아플리버셉트) 주사제 사용을 승인했다고 발표했습니다.
보고서 구매 이유

• 질병 유형, 치료 유형, 유통 채널 및 지역별 글로벌 망막 신생혈관 시장 세분화를 시각화하고 주요 상업 자산 및 기업을 파악하기 위해

• 트렌드 분석 및 공동 개발을 통해 사업 기회를 식별하기 위해 • 모든 세그먼트를 포함한 망막 신생혈관 시장 수준의 다양한 데이터가 담긴 엑셀 데이터 시트.

• 심층적인 질적 인터뷰와 연구를 바탕으로 한 종합적인 분석이 담긴 PDF 보고서.

• 주요 업체들의 핵심 제품을 모두 포함하는 제품 맵핑 엑셀 파일 제공.
글로벌 망막 신생혈관 시장 보고서는 약 55개의 표, 56개의 그림, 186페이지 분량으로 구성됩니다.
주요 고객 (2023년 기준)
• 제조업체/구매자
• 산업 투자자/투자은행
• 연구 전문가
• 신흥 기업

보고서 요약(영어 원문)

Overview
The Global Retinal Neovascularization Market reached US$ YY million in 2022 and is expected to reach US$ YY million by 2030, growing with a CAGR of YY% during the forecast period 2023-2030.
The pathological disease is known as retinal neovascularization is defined by the aberrant development of new blood vessels in the retina, the light-sensitive tissue at the back of the eye. If left untreated, this illness, which is linked to a number of eye conditions, can cause severe vision issues or even blindness.
The development of these aberrant blood vessels can result in a number of problems, including scarring, macular edema, and retinal hemorrhages, which can all seriously impair vision. To stop additional vision loss, retinal neovascularization must be diagnosed and treated in a way.
The retinal neovascularization market is significantly influenced by the increased prevalence of diabetes, particularly in emerging economies. A major contributor to retinal neovascularization is diabetic retinopathy, and the number of patients requiring care grows along with the number of diabetics.
Age-related eye disorders including wet age-related macular degeneration (AMD) are more common in the aging population. The need for treatments to control the retinal neovascularization brought on by these disorders is growing as the world's population ages.
Market Dynamics: Drivers
The Increasing Focus on Diabetic Retinopathy
The most prevalent microangiopathic consequence of diabetes mellitus, diabetes retinopathy (DR), affects more than 100 million people globally and is a significant contributor to visual impairment and legal blindness in developed nations. DR is traditionally divided into proliferative (PDR) and non-proliferative (NPDR) types. The progression from NPDR to PDR is marked by the onset of neovascularization, which is characterized by intraretinal hemorrhages, hard and soft exudates, cotton-wool spots, microaneurysms, venous calibre abnormalities, intraretinal microvascular anomalies, and both macular and peripheral capillary nonperfusion.
VEGF enhances the phosphorylation of tight junction proteins, increasing the permeability of retinal capillaries. Additionally, enhanced transcytosis, activated NOS-mediated processes, induced changes of various intercellular molecules, including occludin, catenins, and cadherins, as well as increased transcytosis all contribute to VEGF-related hyperpermeability. All of these VEGF-related phenomena, which are primarily controlled by VEGF-A isoforms, together with an incredibly complicated series of additional activities and mediators cause DME, a common DR-related complication, to start and progress.
The first medication to receive FDA approval for the intravitreal treatment of retinal disorders was pegaptanib (Macugen, Eyetech/Pfizer). This substance is a pegylated aptamer that binds to the heparin-binding domain of VEGF165 isoform with preference.
Limited Patient Awareness
Delays in diagnosis and the start of treatment may result from patients and healthcare professionals being unaware of the signs and dangers of retinal neovascularization. There may be limited availability to specialist eye care facilities and qualified ophthalmologists in some areas, especially in low-resource settings, which might cause treatment to be delayed or fall short of expectations. Treatments for retinal neovascularization, such as anti-VEGF injections, may come with risks and adverse effects like infection, retinal detachment, and increased intraocular pressure. Some patients may choose not to seek therapy because of these dangers.
Segment Analysis
The global retinal neovascularization market is segmented based on product type, end-user, and region.
The anti-VEGF therapies segment accounted for approximately 48.4% of the market share
Aflibercept (Eylea; Regeneron), ranibizumab (Lucentis; Genentech, California), and bevacizumab (Avastin; Genentech) are the most frequently used VEGF-A pathway treatments available for AMD. The approach to treating wet AMD has been changed by anti-VEGF drugs.
Bevacizumab is a fully humanized immunoglobulin G1 (IgG1) molecule of 148 kDa that binds VEGF-A isoforms under the brand name Avastin from Hoffmann-La Roche. This antibody was initially created for the treatment of cancer. Its intravitreal application for retinal conditions is still regarded as "off-label" therapy. Bevacizumab functions as a pure anti-VEGF antibody, and its major effects are to inhibit the neovascular stimulation and VEGF-induced enhanced vascular permeability. The mechanisms of action are rather straightforward.
Anti-VEGF medications are considered to be the standard of care for treating wet AMD, but in practice, the expenses associated with treating wet AMD frequently make it difficult to achieve the best possible clinical results. The cost of current anti-VEGF medicines may be reduced by the development of biosimilars, which are biologics with equivalent efficacy and safety to reference biologics.
Despite the fact that anti-VEGF treatment is useful and effective for a variety of retinal illnesses, patients and the healthcare system are significantly burdened by the need for repeated intravitreal medication injections due to their high cost and intrusive nature.
Geographical Analysis
Advanced Healthcare Infrastructure
North America has been a dominant force in the global retinal neovascularization market. Between 1,100 and 1,500 newborns in the U.S. experience ROP that is severe enough to call for medical attention. Infants who are born before 31 weeks of pregnancy or who are under 1,500 grams (3.3 lbs) at birth are frequently affected by this rare eye illness. These newborns are at danger of developing aberrant retinal blood vessels (retinal neovascularization), which could result in retinal detachment and irreversible vision loss. Retinal blood vessels are frequently only fully developed after an infant is full-term (9 months of pregnancy). ROP can sometimes improve on its own in mild cases, but in more severe cases, treatment may be necessary to prevent major blindness and visual impairment.
In June 2022, Biogen Inc. and Samsung Bioepis Co., Ltd. launched BYOOVIZ (ranibizumab-nuna), a biosimilar referencing LUCENTIS (ranibizumab), in the United States. BYOOVIZ is commercially available from July 2022, through significant distributors throughout the U.S. Healthcare provider involvement, promotional activity, cooperation with professional associations, and patient advocacy groups have already begun. In September 2021, the FDA authorized BYOOVIZ for the treatment of myopic choroidal neovascularization, macular edema following retinal vein occlusion, and neovascular (wet) age-related macular degeneration (AMD).
In April 2023, Adverum Biotechnologies, Inc., a clinical-stage company, stated nonclinical data in support of the two doses of ixoberogene soroparvovec (Ixo-vec, formerly known as ADVM-022) being assessed in the Phase 2 LUNA trial as well as the potential for staggered, bilateral administration in the treatment of wet AMD.
COVID-19 Impact Analysis
The outbreak of the COVID-19 pandemic in late 2019 created unprecedented challenges for industries worldwide, including the global retinal neovascularization market. There were delays in the detection and treatment of retinal neovascularization and associated eye problems because of lockdowns, restrictions, and patients' anxiety about attending healthcare institutions during the epidemic.
The pandemic may have caused clinical studies for novel therapeutics to be postponed or temporarily stopped, which could have had an impact on the development of new medications and their possible market introduction.
Competitive Landscape
The major global players in the market include Regeneron Pharmaceuticals Inc., Biogen, Notal Vision, Inc., Novartis AG, Adverum Biotechnologies, Inc., Genentech, Inc., Bayer AG, and Others.
Key Developments
• In February 2023, Regeneron Pharmaceuticals, Inc. declared that the U.S. Food and Drug Administration has authorized EYLEA (aflibercept) Injection to treat preterm infants with retinopathy of prematurity.
Why Purchase the Report?
• To visualize the global retinal neovascularization market segmentation based on disease type, treatment type, distribution channel and region as well as understand key commercial assets and players.
• Identify commercial opportunities by analyzing trends and co-development.
• Excel data sheet with numerous data points of retinal neovascularization market-level with all segments.
• PDF report consists of a comprehensive analysis after exhaustive qualitative interviews and an in-depth study.
• Product mapping available as excel consisting of key products of all the major players.
The global retinal neovascularization market report would provide approximately 55 tables, 56 figures, and 186 Pages.
Target Audience 2023
• Manufacturers/ Buyers
• Industry Investors/Investment Bankers
• Research Professionals
• Emerging Companies

상세 목차

Table of Contents
1. Methodology and Scope
1.1. Research Methodology
1.2. Research Objective and Scope of the Report
2. Definition and Overview
3. Executive Summary
3.1. Snippet by Disease Type
3.2. Snippet by Treatment Type
3.3. Snippet by Distribution Channel
3.4. Snippet by Region
4. Dynamics
4.1. Impacting Factors
4.1.1. Drivers
4.1.1.1. The Increasing Focus on Diabetic Retinopathy
4.1.1.2. YY
4.1.2. Restraints
4.1.2.1. Limited Patient Awareness
4.1.2.2. YY
4.1.3. Opportunity
4.1.4. Impact Analysis
5. Industry Analysis
5.1. Porter's Five Force Analysis
5.2. Supply Chain Analysis
5.3. Pricing Analysis
5.4. Regulatory Analysis
5.5. Russia-Ukraine War Impact Analysis
5.6. SWOT Analysis
5.7. Patent Analysis
5.8. DMI Opinion
6. COVID-19 Analysis
6.1. Analysis of COVID-19
6.1.1. Scenario Before COVID
6.1.2. Scenario During COVID
6.1.3. Scenario Post COVID
6.2. Pricing Dynamics Amid COVID-19
6.3. Demand-Supply Spectrum
6.4. Government Initiatives Related to the Market During Pandemic
6.5. Manufacturers Strategic Initiatives
6.6. Conclusion
7. By Disease Type
7.1. Introduction
7.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
7.1.2. Market Attractiveness Index, By Disease Type
7.2. Age-Related Macular Degeneration (AMD)*
7.2.1. Introduction
7.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
7.3. Diabetic Retinopathy
7.4. Retinal Vein Occlusion
7.5. Others
8. By Treatment Type
8.1. Introduction
8.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
8.1.2. Market Attractiveness Index, By Treatment Type
8.2. Anti- VEGF Therapies*
8.2.1. Introduction
8.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
8.2.3. Ranibizumab
8.2.4. Afliberscept
8.3. Corticosteroids
8.4. Others
9. By Distribution Channel
9.1. Introduction
9.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
9.1.2. Market Attractiveness Index, By Distribution Channel
9.2. Hospital Pharmacies*
9.2.1. Introduction
9.2.2. Market Size Analysis and Y-o-Y Growth Analysis (%)
9.3. Retail Pharmacies
9.4. Others
10. By Region
10.1. Introduction
10.1.1. Market Size Analysis and Y-o-Y Growth Analysis (%), By Region
10.1.2. Market Attractiveness Index, By Region
10.2. North America
10.2.1. Introduction
10.2.2. Key Region-Specific Dynamics
10.2.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.2.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.2.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.2.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.2.6.1. U.S.
10.2.6.2. Canada
10.2.6.3. Mexico
10.3. Europe
10.3.1. Introduction
10.3.2. Key Region-Specific Dynamics
10.3.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.3.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.3.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.3.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.3.6.1. Germany
10.3.6.2. UK
10.3.6.3. France
10.3.6.4. Italy
10.3.6.5. Spain
10.3.6.6. Rest of Europe
10.4. South America
10.4.1. Introduction
10.4.2. Key Region-Specific Dynamics
10.4.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.4.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.4.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.4.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.4.6.1. Brazil
10.4.6.2. Argentina
10.4.6.3. Rest of South America
10.5. Asia-Pacific
10.5.1. Introduction
10.5.2. Key Region-Specific Dynamics
10.5.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.5.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.5.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
10.5.6. Market Size Analysis and Y-o-Y Growth Analysis (%), By Country
10.5.6.1. China
10.5.6.2. India
10.5.6.3. Japan
10.5.6.4. Australia
10.5.6.5. Rest of Asia-Pacific
10.6. Middle East and Africa
10.6.1. Introduction
10.6.2. Key Region-Specific Dynamics
10.6.3. Market Size Analysis and Y-o-Y Growth Analysis (%), By Disease Type
10.6.4. Market Size Analysis and Y-o-Y Growth Analysis (%), By Treatment Type
10.6.5. Market Size Analysis and Y-o-Y Growth Analysis (%), By Distribution Channel
11. Competitive Landscape
11.1. Competitive Scenario
11.2. Market Positioning/Share Analysis
11.3. Mergers and Acquisitions Analysis
12. Company Profiles
12.1. Regeneron Pharmaceuticals Inc.*
12.1.1. Company Overview
12.1.2. Product Portfolio and Description
12.1.3. Financial Overview
12.1.4. Key Developments
12.2. Biogen
12.3. Notal Vision, Inc.
12.4. Novartis AG
12.5. Adverum Biotechnologies, Inc.,
12.6. Genentech, Inc.
12.7. Bayer AG
12.8. Others
LIST NOT EXHAUSTIVE
13. Appendix
13.1. About Us and Services
13.2. Contact Us

언급된 주요 기업들

Regeneron Pharmaceuticals Inc., 4. Key Developments, Biogen, Notal Vision, Inc., Novartis AG, Adverum Biotechnologies, Inc.,, Genentech, Inc., Bayer AG, Others

표 목록 (Tables)

List of Tables

Table 1 Global Retinal Neovascularization Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 2 Global Retinal Neovascularization Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 3 Global Retinal Neovascularization Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 4 Global Retinal Neovascularization Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 5 Global Retinal Neovascularization Market Value, By Disease Type, 2022, 2026 & 2030 (US$ Million)

Table 6 Global Retinal Neovascularization Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 7 Global Retinal Neovascularization Market Value, By Treatment Type, 2022, 2026 & 2030 (US$ Million)

Table 8 Global Retinal Neovascularization Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 9 Global Retinal Neovascularization Market Value, By Distribution Channel, 2022, 2026 & 2030 (US$ Million)

Table 10 Global Retinal Neovascularization Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 11 Global Retinal Neovascularization Market Value, By Region, 2022, 2026 & 2030 (US$ Million)

Table 12 Global Retinal Neovascularization Market Value, By Region, 2021-2030 (US$ Million)

Table 13 North America Retinal Neovascularization Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 14 North America Retinal Neovascularization Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 15 North America Retinal Neovascularization Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 16 North America Retinal Neovascularization Market Value, By Country, 2021-2030 (US$ Million)

Table 17 South America Retinal Neovascularization Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 18 South America Retinal Neovascularization Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 19 South America Retinal Neovascularization Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 20 South America Retinal Neovascularization Market Value, By Country, 2021-2030 (US$ Million)

Table 21 Europe Retinal Neovascularization Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 22 Europe Retinal Neovascularization Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 23 Europe Retinal Neovascularization Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 24 Europe Retinal Neovascularization Market Value, By Country, 2021-2030 (US$ Million)

Table 25 Asia-Pacific Retinal Neovascularization Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 26 Asia-Pacific Retinal Neovascularization Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 27 Asia-Pacific Retinal Neovascularization Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 28 Asia-Pacific Retinal Neovascularization Market Value, By Country, 2021-2030 (US$ Million)

Table 29 Middle East & Africa Retinal Neovascularization Market Value, By Disease Type, 2021-2030 (US$ Million)

Table 30 Middle East & Africa Retinal Neovascularization Market Value, By Treatment Type, 2021-2030 (US$ Million)

Table 31 Middle East & Africa Retinal Neovascularization Market Value, By Distribution Channel, 2021-2030 (US$ Million)

Table 32 Regeneron Pharmaceuticals Inc.: Overview

Table 33 Regeneron Pharmaceuticals Inc.: Product Portfolio

Table 34 Regeneron Pharmaceuticals Inc.: Key Developments

Table 35 Biogen: Overview

Table 36 Biogen: Product Portfolio

Table 37 Biogen: Key Developments

Table 38 Notal Vision, Inc.: Overview

Table 39 Notal Vision, Inc.: Product Portfolio

Table 40 Notal Vision, Inc.: Key Developments

Table 41 Novartis AG: Overview

Table 42 Novartis AG: Product Portfolio

Table 43 Novartis AG: Key Developments

Table 44 Adverum Biotechnologies, Inc.: Overview

Table 45 Adverum Biotechnologies, Inc.: Product Portfolio

Table 46 Adverum Biotechnologies, Inc.: Key Developments

Table 47 Genentech, Inc.: Overview

Table 48 Genentech, Inc.: Product Portfolio

Table 49 Genentech, Inc.: Key Developments

Table 50 Bayer AG: Overview

Table 51 Bayer AG: Product Portfolio

Table 52 Bayer AG: Key Developments

Table 53 Others: Overview

Table 54 Others: Product Portfolio

Table 55 Others: Key Developments

그림 목록 (Figures)

List of Figures

Figure 1 Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 2 Global Retinal Neovascularization Market Share, By Disease Type, 2022 & 2030 (%)

Figure 3 Global Retinal Neovascularization Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 4 Global Retinal Neovascularization Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 5 Global Retinal Neovascularization Market Share, By Region, 2022 & 2030 (%)

Figure 6 Global Retinal Neovascularization Market Y-o-Y Growth, By Disease Type, 2022-2030 (%)

Figure 7 Age-Related Macular Degeneration (AMD) Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 8 Diabetic Retinopathy Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 9 Retinal Vein Occlusion Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 10 Others Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 11 Global Retinal Neovascularization Market Y-o-Y Growth, By Treatment Type, 2022-2030 (%)

Figure 12 Anti-VEGF Therapies Treatment Type in Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 13 Corticosteroids Treatment Type in Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 14 Others Treatment Type in Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 15 Global Retinal Neovascularization Market Y-o-Y Growth, By Distribution Channel, 2022-2030 (%)

Figure 16 Hospital Pharmacies Distribution Channel in Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 17 Retail Pharmacies Distribution Channel in Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 18 Others Distribution Channel in Global Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 19 Global Retinal Neovascularization Market Y-o-Y Growth, By Region, 2022-2030 (%)

Figure 20 North America Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 21 Asia-Pacific Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 22 Europe Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 23 South America Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 24 Middle East and Africa Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 25 North America Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 26 North America Retinal Neovascularization Market Share, By Disease Type, 2022 & 2030 (%)

Figure 27 North America Retinal Neovascularization Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 28 North America Retinal Neovascularization Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 29 North America Retinal Neovascularization Market Share, By Country, 2022 & 2030 (%)

Figure 30 South America Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 31 South America Retinal Neovascularization Market Share, By Disease Type, 2022 & 2030 (%)

Figure 32 South America Retinal Neovascularization Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 33 South America Retinal Neovascularization Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 34 South America Retinal Neovascularization Market Share, By Country, 2022 & 2030 (%)

Figure 35 Europe Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 36 Europe Retinal Neovascularization Market Share, By Disease Type, 2022 & 2030 (%)

Figure 37 Europe Retinal Neovascularization Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 38 Europe Retinal Neovascularization Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 39 Europe Retinal Neovascularization Market Share, By Country, 2022 & 2030 (%)

Figure 40 Asia-Pacific Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 41 Asia-Pacific Retinal Neovascularization Market Share, By Disease Type, 2022 & 2030 (%)

Figure 42 Asia-Pacific Retinal Neovascularization Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 43 Asia-Pacific Retinal Neovascularization Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 44 Asia-Pacific Retinal Neovascularization Market Share, By Country, 2022 & 2030 (%)

Figure 45 Middle East & Africa Retinal Neovascularization Market Value, 2021-2030 (US$ Million)

Figure 46 Middle East & Africa Retinal Neovascularization Market Share, By Disease Type, 2022 & 2030 (%)

Figure 47 Middle East & Africa Retinal Neovascularization Market Share, By Treatment Type, 2022 & 2030 (%)

Figure 48 Middle East & Africa Retinal Neovascularization Market Share, By Distribution Channel, 2022 & 2030 (%)

Figure 49 Regeneron Pharmaceuticals Inc.: Financials

Figure 50 Biogen: Financials

Figure 51 Notal Vision, Inc.: Financials

Figure 52 Novartis AG: Financials

Figure 53 Adverum Biotechnologies, Inc.: Financials

Figure 54 Genentech, Inc.: Financials

Figure 55 Bayer AG: Financials

Figure 56 Others: Financials

세계 망막 신생혈관 시장 -2023-2030

Global Retinal Neovascularization Market -2023-2030